Secunderabad Chronicle

Systemic Lupus Erythematosus Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Systemic Lupus Erythematosus Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 15
22:36 2022
Systemic Lupus Erythematosus Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Systemic Lupus Erythematosus pipeline constitutes 60+ key companies continuously working towards developing 60+ Systemic Lupus Erythematosus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Systemic Lupus Erythematosus Overview

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms.

 

Systemic Lupus Erythematosus Pipeline Insight, 2022 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market. 

 

The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years. Systemic Lupus Erythematosus Key players such as – I-Mab Biopharma, Pfizer, Equillium, Biocon Limited, Kangpu Biopharmaceuticals, InnoCare Pharma, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Bristol Myers Squibb, Sanofi, Biogen, Eli Lilly and Company, Hoffman-La-Roche, and others, are developing therapies for the Systemic Lupus Erythematosus treatment 
  • Systemic Lupus Erythematosus Emerging therapies such as – TJ202, PF-06835375, Itolizumab, KPG 818, ICP-022, BOS16172, NKTR-358, ABBV-599, Deucravacitinib, SAR441344, BIIB059, Baricitinib, Obinutuzumab, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.   
  • In September 2019, Eli Lilly and company initiated a Phase III, Double-Blind, Multicenter Study to Evaluate theLong-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus. 

 

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment

  • Systemic Lupus Erythematosus Assessment by Product Type
  • Systemic Lupus Erythematosus By Stage and Product Type
  • Systemic Lupus Erythematosus Assessment by Route of Administration
  • Systemic Lupus Erythematosus By Stage and Route of Administration
  • Systemic Lupus Erythematosus Assessment by Molecule Type
  • Systemic Lupus Erythematosus by Stage and Molecule Type

 

DelveInsight’s Systemic Lupus Erythematosus Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:

  • TJ202: I-Mab Biopharma
  • PF-06835375: Pfizer
  • Itolizumab: Equillium/ Biocon Limited
  • KPG 818: Kangpu Biopharmaceuticals
  • ICP-022: InnoCare Pharma
  • BOS161721: Boston Pharmaceuticals
  • NKTR-358: Nektar Therapeutics
  • ABBV-599: AbbVie
  • Deucravacitinib: Bristol Myers Squibb
  • SAR441344: Sanofi
  • BIIB059: Biogen
  • Baricitinib: Eli Lilly and Company
  • Obinutuzumab: Hoffman-La-Roche 

 

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Assessment https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

 

Systemic Lupus Erythematosus Pipeline Analysis:

The Systemic Lupus Erythematosus pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Systemic Lupus Erythematosus treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
  • Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies

 

Systemic Lupus Erythematosus Pipeline Market Drivers

  • Increasing burden of the disease
  • New drugs under pipeline
  • Favorable Medicare coverage

 

Systemic Lupus Erythematosus Pipeline Market Barriers

  • High cost of Systemic Lupus Erythematosus treatment
  • Strict guidelines for Systemic Lupus Erythematosus
  • Need of skilled professionals

 

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight    

  • Coverage: Global
  • Key Systemic Lupus Erythematosus Companies: I-Mab Biopharma, Pfizer, Equillium, Biocon Limited, Kangpu Biopharmaceuticals, InnoCare Pharma, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Bristol Myers Squibb, Sanofi, Biogen, Eli Lilly and Company, Hoffman-La-Roche, and others
  • Key Systemic Lupus Erythematosus Therapies: TJ202, PF-06835375, Itolizumab, KPG 818, ICP-022, BOS16172, NKTR-358, ABBV-599, Deucravacitinib, SAR441344, BIIB059, Baricitinib, Obinutuzumab, and others
  • Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
  • Systemic Lupus Erythematosus Market Dynamics:  Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers 

 

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials

 

Table of Contents

1

Systemic Lupus Erythematosus Report Introduction

2

Systemic Lupus Erythematosus Executive Summary

3

Systemic Lupus Erythematosus Overview

4

Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment

5

Systemic Lupus Erythematosus Pipeline Therapeutics

6

Systemic Lupus Erythematosus Late Stage Products (Phase II/III)

7

Systemic Lupus Erythematosus Mid Stage Products (Phase II)

8

Systemic Lupus Erythematosus Early Stage Products (Phase I)

9

Systemic Lupus Erythematosus Preclinical Stage Products

10

Systemic Lupus Erythematosus Therapeutics Assessment

11

Systemic Lupus Erythematosus Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Systemic Lupus Erythematosus Key Companies

14

Systemic Lupus Erythematosus Key Products

15

Systemic Lupus Erythematosus Unmet Needs

16 

Systemic Lupus Erythematosus Market Drivers and Barriers

17

Systemic Lupus Erythematosus Future Perspectives and Conclusion

18

Systemic Lupus Erythematosus Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles